Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access to Ziftomenib

NCT05738538 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT05738538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05738538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access to Ziftomenib
Lead sponsor
Kura Oncology, Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, with kmt2a rearrangements, acute myeloid leukemia, with kmt2a rearrangements, acute myeloid leukemia, with npm1 mutations